Skip to main content
Figure 5 | Nutrition & Metabolism

Figure 5

From: Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

Figure 5

Linear fit of change from Baseline at Day 90 in ADAS-Cog score and log transformed total dosage stratified by APOE4 carriage status. Only reported ADAS-Cog scores were used; no data was imputed. Solid circles represent APOE4(+) subjects, open circles represent APOE4(-) subjects. Crosses represent non-dosage compliant subjects. Red line indicates linear fit for all genotypes, green line for APOE4(-) subjects, and blue line for APOE4(+) subjects. A) Among subjects taking AC-1202, a significant correlation was found in APOE4(-) subjects in change from Baseline at Day 90 in ADAS-Cog score and log transformed total dosage. B) Among subjects taking Placebo, no significant correlations were found in change from Baseline at Day 90 in ADAS-Cog score and log transformed total dosage.

Back to article page